Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Priorix

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Measles-Mumps-Rubella Vaccine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
BACKGROUND Chikungunya is an emerging arthropod-borne disease that has spread from tropical endemic areas to more temperate… Expand
  • figure 1
  • table 1
  • figure 3
  • table 3
  • table 2
Highly Cited
2014
Highly Cited
2014
Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
BACKGROUND In July 2006, Priorix-Tetra™, a combined measles-mumps-rubella-varicella (MMRV) vaccine, was licensed in Germany… Expand
2011
2011
Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine: Follow-up of a Randomized Controlled Trial
Background: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) wane after early… Expand
2011
2011
Reappraisal of MMR vaccines currently used in Korea
Background:  Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated… Expand
Highly Cited
2007
Highly Cited
2007
Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
Measles-mumps-rubella (MMR) vaccines containing the Urabe strain of mumps were withdrawn in the United Kingdom in 1992 following… Expand
  • table 2
Highly Cited
2006
Highly Cited
2006
Immunogenicity and Safety of Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children
Background: Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more… Expand
2006
2006
Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
The aim of this study was to investigate whether, the vaccine Priorix causes less immediate injection pain than MMR-II in… Expand
2004
2004
Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants.
OBJECTIVE To compare acute pain response to 2 measles-mumps-rubella vaccines. DESIGN Double-blind clinical trial. SETTING… Expand
  • table 1
  • table 2
  • table 4
  • table 3
2004
2004
Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children.
The aim of this study was to compare self-reported immediate post-vaccination pain and safety of Priorix versus RORVax in 4- to 6… Expand
Highly Cited
1999
Highly Cited
1999
Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
OBJECTIVE To compare the reactogenicity and immunogenicity of a novel live attenuated measles-mumps-rubella vaccine, SB MMR… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE